

Electronic Supporting Information

for

Synthesis of nucleoside and nucleotide conjugates of bile acids and polymerase construction of bile acid-functionalized DNA

Satu Ikonen, Hana Macíčková-Cahová, Radek Pohl, and Michal Hocek*

Table of contents:

1. Full experimental part	S2
2. MALDI-TOF experiment (ssDNA)	S12
3. Sequence analysis of PCR products	S13
3. Supplementary PAGE figures	S15
4. Tables of NMR data	S16
5. Copies of NMR spectra	S22

General

NMR spectra were measured on a Bruker Avance 600 (600.1 MHz for ^1H and 150.9 MHz for ^{13}C nuclei) and a Bruker Avance 500 (500.1, 500.0, 499.8 MHz for ^1H , 125.7 MHz for ^{13}C and 202.3 for ^{31}P nuclei) in CDCl_3 (referenced to solvent signals $\delta_{\text{H}} = 7.26$ ppm, $\delta_{\text{C}} = 77.0$ ppm), CD_3OD (referenced to solvent signals $\delta_{\text{H}} = 3.31$ ppm, $\delta_{\text{C}} = 69.3$ ppm) and D_2O (reference to dioxane as an internal standard, $\delta_{\text{H}} = 3.75$ ppm, $\delta_{\text{C}} = 69.3$ ppm, standard for ^{31}P NMR was external H_3PO_4). Chemical shifts are given in ppm (δ -scale), and coupling constants (J) in Hz. Mass spectra were measured on LCQ classic (Thermo/Finnigan) spectrometer using ESI. Preparative HPLC separations were performed on a column packed with 10 μm C18 reversed phase (Phenomenex, Luna C18(2)).

Synthesis

Starting compound **2b** was prepared as described previously.¹ Triphosphorylation of iododeoxynucleosides (**dA^ITP** and **dC^ITP**) were performed utilizing known procedures.²

Synthesis of Bile acid acetylenes

Method A: Bile acid 1 (10.0 mmol) and Cs_2CO_3 (15.0 mmol) suspended with 35 mL of DMF were stirred at rt for 1 h. Propargyl bromide (80 % in toluene, 20.0 mmol) was added and the stirring continued for 20 hours. Mixture was dissolved in 100 mL of CHCl_3 and washed with 3x50 mL of H_2O and 50 mL of Brine, dried over anhydrous Na_2SO_4 and evaporated to give oily crude product which was purified by column chromatography. Products were crystallized from CH_3CN as white solids which were dried in *vacuo*.

Method B: Bile acid 1 (10.0 mmol) was suspended with dry dioxane, triethyl amine (1.53 mL, 11.0 mmol) was added and the mixture cooled to 10°C. Through a dropping funnel ethyl chloroformate (1.05 mL, 11.0 mmol) was added dropwise after which the stirring was continued for 30 min at 10°C. Propargyl amide (1.23 mL, 20 mmol) in 10 mL of dioxane was added dropwise to the reaction mixture and the mixture was allowed to spontaneously reach room temperature after which the stirring was continued for another 20 h. Mixture was then evaporated and the residue dissolved in 200 mL of CHCl_3 , washed with 100 mL of H_2O , 4x50 mL of 0.1 M HCl, 2x100 mL H_2O and 100 mL of Brine, dried over anhydrous Na_2SO_4 and evaporated to give crude product which was purified by column chromatography.

Propargyl 3 α ,7 α ,12 α -trihydroxy-5 β -cholan-24-oate (**2a**)¹

Prepared by Method A from **1a** and purified by column chromatography using CH₃OH (2-20 % gradient) in CH₂Cl₂ as an eluent. Yield 73 % of **2a** as white solid. δ_{H} (500.1 MHz; CDCl₃) ppm: 0.68 (s, 3H, 18''CH₃), 0.89 (s, 3H, 19''CH₃), 0.98 (d, $J=6.0$, 3H, 21''CH₃), 0.98-2.46 (steroidal -CH₂- and -CH-, 3''C-OH, 7''C-OH, 12''C-OH, 23''CH₂, 27''CH), 3.44 (m, 1H, 3''CH), 3.85 (br.s, 1H, 7''CH), 3.96 (br.s, 1H, 12''CH), 4.65 (s, 2H, 25''CH₂); δ_{C} (125.8 MHz; CDCl₃) ppm: 12.5 (C18''), 17.3 (C21''), 22.5 (C19''), 23.2 (C15''), 26.6 (C9''), 27.4 (C16''), 28.3 (C11''), 30.6 (C2''), 30.8 (C22''), 31.0 (C23''), 34.7 (C6'' and C10''), 35.1 (C20''), 35.3 (C1''), 39.6 (C8''), 39.7 (C4''), 41.5 (C5''), 41.9 (C14''), 46.5 (C13''), 47.1 (C17''), 51.7 (C25''), 68.4 (C12''), 71.9 (C3''), 73.0 (C7''), 74.7 (C27''), 77.9 (C26''), 173.3 (C24''); MS (ES⁺): found m/z : 469.3 ([M+Na]⁺), 485.3 ([M+K]⁺).

Propargyl 3 α ,7 α -dihydroxy-5 β -cholan-24-oate (**2c**)

Bile acid **1c** (3.93 g, 10.0 mmol) and Cs₂CO₃ (4.89 g, 15.0 mmol) suspended with 35 mL of DMF were stirred at rt for 1 h. Propargyl bromide (2.97 g, 80 w% in toluene, 20.0 mmol) was added and the stirring continued for 20 hours. Mixture was dissolved in 100 mL of CHCl₃ and washed with 3x50 mL of H₂O and 50 mL of Brine, dried over anhydrous Na₂SO₄ and evaporated to give oily crude product which was purified by column chromatography using CH₃OH (2-10 %) in CH₂Cl₂ as an eluent. Product was crystallized from CH₃CN and dried *in vacuo* to give **2c** (1.95 g, 45 %) as a white solid. Found: C, 75.2; H, 9.7. (C₂₇H₄₂O₄ requires C, 75.3; H, 9.8); $\nu(\text{KBr})/\text{cm}^{-1}$: 3429, 3310, 2931, 2866, 2129, 1743, 1638, 1626, 1466, 1449, 1418, 1377, 1328, 1307, 1244, 1161, 1078, 1030, 1001, 980, 899, 859, 764; δ_{H} (500.1 MHz; CDCl₃) ppm: 0.64 (s, 3H, 18''CH₃), 0.89 (s, 3H, 19''CH₃), 0.91 (d, $J=6.5$, 3H, 21''CH₃), 0.92-2.42 (steroidal -CH₂- and -CH-, 3''C-OH, 7''C-OH, 23''CH₂), 2.37 (t, $J=5$ Hz, 1H, 27''CH), 3.43 (m, 1H, 3''CH), 3.83 (m, 1H, 7''CH), 4.65 (m, 2H, 25''CH₂); δ_{C} (126 MHz; CDCl₃) ppm: 11.7 (C18''), 18.2 (C19''), 20.6 (C11''), 22.7 (C21''), 23.6 (C15''), 28.1 (C16''), 30.7 (C6''), 30.8 (C22''), 30.9 (C23''), 32.8 (C8''), 34.6 (C2''), 35.0 (C10''), 35.3 (C1'' and C20''), 39.4 (C5''), 39.6 (C12''), 39.8 (C4''), 41.5 (C9''), 42.7 (C13''), 50.4 (C14''), 51.7 (C25''), 55.8 (C17''), 68.4 (C3''), 71.9 (C7''), 74.6 (d, C27''), 77.9 (C26''), 173.3 (C24''); MS (ES⁺): found m/z : 453.3 ([M+Na]⁺), 469.3 ([M+K]⁺).

N-Propargyl 3 α ,7 α ,12 α -trihydroxy-24-oxo-5 β -cholan-24-amide (**2d**)³

Prepared by method b from **1d** and purified by column chromatography using CH₃OH (20 %) in CH₂Cl₂ as an eluent. Yield 49 % of **2d** as white solid. δ_{H} (500.1 MHz; CD₃OD) ppm: 0.67 (s, 3H,

18''CH₃), 0.88 (s, 3H, 19''CH₃), 0.99 (d, *J*=6.5, 3H, 21''CH₃), 0.95-2.60 (steroidal -CH₂- and -CH-), 2.08-2.28 (m, 2H, 23''CH₂), 2.54 (t, *J*=2.5, 1H, 27''CH), 3.53 (m, 1H, 3''CH), 3.93 (d, *J*=2.5, 2H, 25''CH₂), 3.95 (m, 1H, 12''CH); δ_C (125.8 MHz; CDCl₃) ppm: 12.5 (C18''), 17.5 (C21''), 22.5 (C19''), 23.3 (C15''), 26.5 (C9''), 27.6 (C16''), 28.2 (C11''), 29.1 (C25''), 30.5 (C2''), 31.4 (C22''), 32.8 (C23''), 34.7 (C6''), 34.7 (C10''), 35.3 (C1''), 35.3 (C20''), 39.5 (C8''), 39.7 (C4''), 41.5 (C5''), 41.8 (C14''), 46.5 (C13''), 46.6 (C17''), 68.4 (C12''), 71.3 (C27''), 71.9 (C3''), 73.1 (C7''), 79.9 (C26''), 173.6 (C24''); MS (ES⁺): found *m/z*: 468.4 ([M+Na]⁺), 484.4 ([M+K]⁺).

***N*-Propargyl 3α,12α-dihydroxy-24-oxo-5β-cholan-24-amide (2e)³**

Prepared by method b and purified by column chromatography using CH₃OH (2-6 % gradient) in CH₂Cl₂ as an eluent. Yield 50 % of **2e** as white solid. δ_H (500.1 MHz; CDCl₃) ppm: 0.71 (s, 3H, 18''CH₃), 0.93 (s, 3H, 19''CH₃), 1.02 (d, *J*=6.5, 3H, 21''CH₃), 0.93-1.90 (steroidal -CH₂- and -CH-, 23''CH₂) 2.23 (t, *J*=2.5, 27''CH), 2.77 (br. s, 3H, 3''C-OH, 7''C-OH, 12''C-OH), 3.34 (m, 1H, 3''CH), 3.83 (br.s, 1H, 7''CH), 3.96 (br.s, 1H, 12''H), 4.04 (m, 2H, 25''CH₂), 6.28 (br.s, 1H, NH); δ_C (125.8 MHz; CDCl₃) ppm: 13.3 (C18''), 17.8 (C21''), 23.8 (C19''), 25.0 (C15''), 27.6 (C16''), 28.6 (C7''), 28.8 (C6''), 29.5 (C25''), 30.1 (C11''), 31.3 (C2''), 33.3 (C22''), 34.0 (C23''), 35.0 (C9''), 35.5 (C10''), 36.6 (C1''), 36.9 (C20''), 37.4 (C4''), 37.6 (C8''), 43.8 (C5''), 47.7 (C13''), 48.3 (C17''), 49.5 (C14''), 72.1 (C27''), 72.7 (C3''), 74.2 (C12''), 80.9 (C26''), 176.6 (C24''); MS (ES⁺): found *m/z*: 452.4 ([M+Na]⁺), 468.3 ([M+K]⁺).

Synthesis of modified nucleosides – Sonogashira cross-coupling – General procedure:

Water/acetonitrile mixture (1.5 mL) was added through a septum to argon-purged vial containing halogenated nucleoside **3-5**, acetylene **2** (1.2-1.5 eqv. to nucleoside), and CuI (10 mol %). In a separate vial Pd(OAc)₂ (5 mmol %) and P(Ph-SO₃Na)₃ (5 eqv. to Pd) were combined under argon with 0.5 mL of H₂O-CH₃CN. After dissolution of the solids, the catalyst solution was added to the reaction mixture followed by addition of EtN(*i*-Pr)₂ (10 eqv.). Reaction mixture was stirred under argon at 65-75 °C for 12-120 min. Mixture was then concentrated and purified by column chromatography and dried *in vacuo* to give **6a-8e**.

7-[(3α,7α,12α-trihydroxy-24-oxo-5β-cholan-24-yl)oxy]prop-1-yn-1-yl}-7-deaza-2'-deoxyadenosine (6a)

Reaction from **2a** (60.0 mg, 0.13 mmol) and **3** (29.6 mg, 0.08 mmol) with CuI (1.9 mg, mmol), Pd(OAc)₂ (1.1 mg, 0.005 mmol), TPPTS (14.2 mg, 0.025 mmol), EtN(*i*-Pr)₂ (130 μL, 0.75 mmol),

in H₂O-CH₃CN (1:1) at 65 °C for 12 min yielded product which was purified by column chromatography using EtOAc-CH₃OH (10:0-10:2) as an eluent and dried *in vacuo* to yield 37.7 mg (69 %) of **6a** as slightly yellowish solid. NMR: Tables S1 and S2. $\nu(\text{KBr})/\text{cm}^{-1}$: 3434, 2936, 2868, 2231, 1733, 1626, 1590, 1571, 1538, 1464, 1450, 1377, 1300, 1196, 1169, 1092, 1077, 1043, 980, 914, 797; MS (ES⁺): found m/z: 695.4 ([M+H]⁺), 717.4 ([M+Na]⁺), 1411.0 ([2M+Na]⁺); HRMS (ES⁻): found m/z: 695.4018 (C₃₈H₅₅O₈N requires 695.4014).

7-{{(3 α ,12 α -dihydroxy-24-oxo-5 β -cholan-24-yl)oxy}prop-1-yn-1-yl}-7-deaza-2'-deoxyadenosine (6b)

Reaction from **2b** (51.7 mg, 0.12 mmol) and **3** (30.1 mg, 0.08 mmol) with CuI (1.5 mg, 0.008 mmol), Pd(OAc)₂ (0.9 mg, 0.004 mmol), TPPTS (11.2 mg, 0.02 mmol), EtN(*i*-Pr)₂ (140 μ L, 0.8 mmol), in H₂O-CH₃CN (1:1) at 65 °C for 20 min yielded product which was purified by column chromatography using EtOAc-CH₃OH (10:0.5-10:4) as an eluent and dried *in vacuo* to yield 19.1 mg (35 %) of **6b** as a slightly yellowish solid. NMR: Tables S1 and S2. $\nu(\text{KBr})/\text{cm}^{-1}$: 3440, 2936, 2865, 2231, 1732, 1626, 1591, 1573, 1537, 1449, 1376, 1300, 1203, 1166, 1094, 1044, 996, 943, 798; MS (ES⁺): found m/z: 679 ([M+H]⁺), 701 ([M+Na]⁺), 1379 ([2M+Na]⁺); HRMS (ES⁺): found m/z: 679.4069 (C₃₈H₅₅O₇N₄ requires 679.4065).

7-{{(3 α ,7 α -dihydroxy-24-oxo-5 β -cholan-24-yl)oxy}prop-1-yn-1-yl}-7-deaza-2'-deoxyadenosine (6c)

Reaction from **2c** (53.3 mg, 0.12 mmol) and **3** (29.6 mg, 0.08 mmol) with CuI (1.4 mg, 0.007 mmol), Pd(OAc)₂ (0.9 mg, 0.004 mmol), TPPTS (11.3 mg, 0.02 mmol), EtN(*i*-Pr)₂ (140 μ L, 0.8 mmol), in H₂O-CH₃CN (1:1) at 65 °C for 15 min yielded product which was purified by column chromatography using EtOAc-CH₃OH (10:0-10:4) as an eluent and dried *in vacuo* to yield 23.6 mg (45 %) **6c** as a slightly yellowish solid. NMR: Tables S1 and S2. $\nu(\text{KBr})/\text{cm}^{-1}$: 3442, 2932, 2867, 2231, 1734, 1626, 1591, 1572, 1537, 1463, 1453, 1376, 1301, 1201, 1164, 1095, 1079, 1059, 798; MS (ES⁺): found m/z: 679.5 ([M+H]⁺), 701.4 ([M+Na]⁺), HRMS (ES⁻): found m/z: 679.4069 (C₃₈H₅₅O₇N₄ requires 679.4065)

7-{{(3 α ,7 α ,12 α -trihydroxy-24-oxo-5 β -cholan-24-yl)amino}prop-1-yn-1-yl}-7-deaza-2'-deoxyadenosine (6d)

Reaction from **2d** (42.5 mg, 0.10 mmol) and **3** (30.6 mg, 0.08 mmol) with CuI (2.2 mg, 0.012 mmol), Pd(OAc)₂ (0.9 mg, 0.004 mmol), TPPTS (11.4 mg, 0.02 mmol), EtN(*i*-Pr)₂ (140 μ L, 0.8

mmol), in H₂O-CH₃CN (2:1) at 75 °C for 60 min yielded product which was purified by column chromatography using EtOAc-CH₃OH (10:1-10:4) as an eluent and dried *in vacuo* to yield 38.3 mg (69 %) of **6d** as slightly yellowish solid. NMR: Tables S1 and S2. $\nu(\text{KBr})/\text{cm}^{-1}$: 3422, 2933, 2863, 2230, 1625, 1590, 1571, 1533, 1449, 1417, 1377, 1301, 1201, 1173, 1090, 1040, 941, 797; MS (ES⁺): found m/z: 694.4 ([M+H]⁺), 716.5 ([M+Na]⁺), 1409.2 ([2M+Na]⁺), HRMS (ES⁺): found m/z: 694.4177 (C₃₈H₅₆N₅O₇ requires 694.4174).

7-{{(3 α ,12 α -dihydroxy-24-oxo-5 β -cholan-24-yl)amino}prop-1-yn-1-yl}-7-deaza-2'-deoxyadenosine (6e)

Reaction from **2e** (43.5 mg, 0.10 mmol) and **3** (31.9 mg, 0.08 mmol) with CuI (2.2 mg, 0.012 mmol), Pd(OAc)₂ (0.9 mg, 0.004 mmol), TPPTS (11.3 mg, 0.02 mmol), EtN(*i*-Pr)₂ (140 μ L, 0.8 mmol), in H₂O-CH₃CN (2:1) at 75 °C for 60 min yielded product which was purified by column chromatography using EtOAc-CH₃OH (10:0-10:2) as an eluent and dried *in vacuo* to yield 37.5 mg (65 %) of **6e** as a slightly yellowish solid. NMR: Tables S1 and S2. $\nu(\text{KBr})/\text{cm}^{-1}$: 3430, 2934, 2866, 2230, 1626, 1591, 1571, 1533, 1461, 1450, 1377, 1301, 1198, 1174, 1090, 1076, 1043, 981, 914, 858, 797; MS (ES⁻): found m/z: 676.3 ([M-H]⁻); HRMS (ES⁻): found m/z: 676.4067 (C₃₈H₅₄N₅O₆ requires 676.4074).

5-{{(3 α ,7 α ,12 α -trihydroxy-24-oxo-5 β -cholan-24-yl)oxy}prop-1-yn-1-yl}-2'-deoxycytidine (7a)

Reaction from **2a** (60.2 mg, 0.13 mmol) and **4** (37.4 mg, 0.11 mmol) with CuI (1.9 mg, 0.01 mmol), Pd(OAc)₂ (1.1 mg, 0.005 mmol), TPPTS (14.2 mg, 0.025 mmol), EtN(*i*-Pr)₂ (174 μ L, 1.0 mmol), in H₂O-CH₃CN (1:1) at 65 °C for 12 min yielded product which was purified by column chromatography using EtOAc-CH₃OH (10:0.5-10:3) as an eluent and dried *in vacuo* to yield 28.0 mg (39 %) **7a** as a white solid. NMR: Tables S3 and S4. $\nu(\text{KBr})/\text{cm}^{-1}$: 3393, 2935, 2868, 1650, 1601, 1506, 1417, 1303, 1259, 1232, 1193, 1092, 1077, 1046, 981, 950, 914, 853, 785; MS (ES⁺): found m/z: 672.3 ([M+H]⁺), 694.4 ([M+Na]⁺), 1343.4 ([2M+H]⁺), 1365.5 ([2M+Na]⁺), MS (ES⁻): found m/z: 670.1 [M-H]⁻, 716.1 [M+OH]⁻; HRMS (ES⁻): found m/z: 670.3702 (C₃₆H₅₂O₉N₃ requires 670.3709).

5-{{(3 α ,12 α -dihydroxy-24-oxo-5 β -cholan-24-yl)oxy}prop-1-yn-1-yl}-2'-deoxycytidine (7b)

Reaction from **2b** (64.6 mg, 0.15 mmol) and **4** (35.9 mg, 0.10 mmol) with CuI (1.9 mg, 0.010 mmol), Pd(OAc)₂ (1.1 mg, 0.005 mmol), TPPTS (14.2 mg, 0.025 mmol), EtN(*i*-Pr)₂ (174 μ L, 1.0 mmol), in H₂O-CH₃CN (1:1) at 65 °C for 20 min yielded product which was purified by column

chromatography using EtOAc-CH₃OH (10:0.5-10:4) as an eluent and dried *in vacuo* to yield 57.9 mg (88 %) of **7b** as a slightly yellowish solid. NMR: Tables S3 and S4. $\nu(\text{KBr})/\text{cm}^{-1}$: 3411, 2934, 2864, 1650, 1602, 1505, 1449, 1417, 1356, 1304, 1258, 1191, 1092, 1043, 945, 851, 785; MS (ES⁺): found m/z: 656.3 ([M+H]⁺), 678.4 ([M+Na]⁺), 1311.4 ([2M+H]⁺), 1333.4 ([2M+Na]⁺); HRMS (ES⁻): found m/z: 653.3919 (C₃₆H₅₄N₄O₇ requires 653.3914).

5-[(3 α ,7 α -dihydroxy-24-oxy-5 β -cholan-24-yl)oxo]prop-1-yn-1-yl}-2'-deoxycytidine (7c**)**

Reaction from **2c** (64.6 mg, 0.15 mmol) and **4** (35.7 mg, 0.10 mmol) with CuI (1.9 mg, 0.010 mmol), Pd(OAc)₂ (1.1 mg, 0.005 mmol), TPPTS (14.2 mg, 0.025 mmol), EtN(*i*-Pr)₂ (174 μ L, 1.0 mmol), in H₂O-CH₃CN (1:1) at 65 °C for 20 min yielded product which was purified by column chromatography using EtOAc-CH₃OH (10:0-10:4) as an eluent and dried *in vacuo* to yield 59.2 mg (90 %) of **7c** as a white solid. NMR: Tables S3 and S4. $\nu(\text{KBr})/\text{cm}^{-1}$: 3425, 2936, 2868, 2232, 1732, 1649, 1602, 1505, 1447, 1416, 1377, 1306, 1259, 1236, 1190, 1153, 1092, 1078, 1045, 1000, 982, 951, 914, 858, 786; MS (ES⁺): found m/z: 656.2 ([M+H]⁺), 678.4 ([M+Na]⁺), 694.3 ([M+K]⁺), 1311.4 ([2M+H]⁺), 1334.3 ([2M+Na]⁺); HRMS (ES⁺): found m/z: 656.3909 (C₃₆H₅₄O₈N₃ requires 656.3905).

5-[(3 α ,7 α ,12 α -trihydroxy-24-oxo-5 β -cholan-24-yl)amino]prop-1-yn-1-yl}-2'-deoxycytidine (7d**)**

Reaction from **2d** (53.8 mg, 0.12 mmol) and **4** (36.9 mg, 0.10 mmol) with CuI (1.9 mg, 0.010 mmol), Pd(OAc)₂ (1.1 mg, 0.005 mmol), TPPTS (14.2 mg, 0.025 mmol), EtN(*i*-Pr)₂ (174 μ L, 1.0 mmol), in H₂O-CH₃CN (2:1) at 75 °C for 60 min yielded product which was purified by column chromatography using CHCl₃-CH₃OH (10:2) as an eluent and dried *in vacuo* to yield 44.6 mg (66 %) of **7d** as a white solid. NMR: Tables S3 and S4. $\nu(\text{KBr})/\text{cm}^{-1}$: 3422, 2935, 2864, 2233, 1733, 1648, 1598, 1057, 1448, 1376, 1307, 1256, 1164, 1092, 1042, 967, 945, 851, 785; MS (ES⁺): found m/z: 671.3 ([M+H]⁺), 693.4 ([M+Na]⁺), 791.0 ([M+K]⁺), 1363.4 ([2M+Na]⁺); HRMS (ES⁻): found m/z: 699.3859 (C₃₆H₅₃N₄O₈ requires 669.3869).

5-[(3 α ,12 α -dihydroxy-24-oxo-5 β -cholan-24-yl)amino]prop-1-yn-1-yl}-2'-deoxycytidine (7e**)**

Reaction from **2e** (61.9 mg, 0.14 mmol) and **4** (42.0 mg, 0.12 mmol) with CuI (1.9 mg, 0.010 mmol), Pd(OAc)₂ (1.1 mg, 0.005 mmol), TPPTS (14.2 mg, 0.025 mmol), EtN(*i*-Pr)₂ (174 μ L, 1.0 mmol), in H₂O-CH₃CN (2:1) at 75 °C for 120 min yielded product which was purified by column chromatography using EtOAc-CH₃OH (10:1-10:4) as an eluent and dried *in vacuo* to yield 48.0 mg

(61 %) of **7e** as a slightly yellowish solid. NMR: Tables S3 and S4. $\nu(\text{KBr})/\text{cm}^{-1}$: 3419, 2829, 2866, 2359, 2341, 2233, 1732, 1649, 1598, 1506, 1448, 1416, 1376, 1308, 1260, 1163, 1091, 1078, 1050, 1000, 979, 955, 900, 860, 785; MS (ES^+): found m/z : 655.3 ($[\text{M}+\text{H}]^+$), 677.4 ($[\text{M}+\text{Na}]^+$), 1309.4 ($[2\text{M}+\text{H}]^+$), 1331.4 ($[2\text{M}+\text{Na}]^+$); HRMS (ES^+): found m/z : 653.3919 ($\text{C}_{36}\text{H}_{54}\text{N}_4\text{O}_7$ requires 653.3914).


5-}{[(3 α ,12 α -dihydroxy-24-oxo-5 β -cholan-24-yl)amino]prop-1-yn-1-yl}-2'-deoxyuridine (8e**) in aqueous phase**

Reaction from **2e** (66.8 mg, 0.16 mmol) and **4** (35.4 mg, 0.10 mmol) with CuI (1.9 mg, 0.010 mmol), Pd(OAc)₂ (1.1 mg, 0.005 mmol), TPPTS (14.2 mg, 0.025 mmol), EtN(*i*-Pr)₂ (174 μL , 1.0 mmol), in H₂O-CH₃CN (1:1) at 65 °C for 20 min yielded product which was purified by column chromatography using EtOAc-CH₃OH (10:0-10:4) as an eluent and dried *in vacuo* to yield 37.9 mg (58 %) of **7a** as a white solid. NMR: Tables S5 and S6. $\nu(\text{KBr})/\text{cm}^{-1}$: 3422, 3066, 2935, 2864, 2363, 2343, 1691, 1534, 1459, 1420, 1377, 1355, 1281, 1194, 1091, 1042, 986, 945, 922, 851, 774, 758; MS (ES^+): found m/z : 678.3 ($[\text{M}+\text{Na}]$), 1333.3 ($[2\text{M}+\text{Na}]^+$); HRMS (ES^+): found m/z : 656.3907 ($\text{C}_{36}\text{H}_{54}\text{N}_3\text{O}_8$ requires 656.3905).

5-}{[(3 α ,12 α -dihydroxy-24-oxo-5 β -cholan-24-yl)amino]prop-1-yn-1-yl}-2'-deoxyuridine (8e**) under anhydrous conditions**

Reaction from **2e** (55.0 mg, 0.13 mmol) and **4** (35.3 mg, 0.10 mmol) with CuI (1.9 mg, 0.010 mmol), Pd(OAc)₂ (1.1 mg, 0.005 mmol), TPPTS (14.2 mg, 0.025 mmol), EtN(*i*-Pr)₂ (174 μL , 1.0 mmol), in dry DMF at 80 °C for 3 h yielded product which was purified by column chromatography using EtOAc-CH₃OH (10:0-10:4) as an eluent and dried *in vacuo* to yield 22.1 mg (31 %) of **7a** as a white solid. NMR: Tables S5 and S6. $\nu(\text{KBr})/\text{cm}^{-1}$: 3419, 3063, 2936, 2865, 2357, 2339, 1694, 1537, 1463, 1416, 1376, 1357, 1282, 1194, 1092, 1042, 986, 946, 920, 852, 806, 776, 758; MS (ES^+): found m/z : 678.4 ($[\text{M}+\text{Na}]^+$), 1333.2 ($[2\text{M}+\text{Na}]^+$) HRMS (ES^+): found m/z : 678.3728 ($\text{C}_{36}\text{H}_{53}\text{N}_3\text{O}_8\text{Na}$ requires 678.3725).

6-}{[(3 α ,7 α ,12 α -trihydroxy-24-oxo-5 β -cholan-24-yl)aminomethyl}-3-(2'- β -D-deoxyribofuranosyl)-furo[2,3-*d*]pyrimidin-2(3*H*)-one nucleoside (9d**)**



Scheme S1. (i) CuI (10 mol%), Pd(OAc)₂ (5 mol%), P(Ph-SO₃Na)₃ (5 eq. to Pd), EtN(*i*-Pr)₂ (10 eq.), H₂O-CH₃CN (2:1), 75 °C, 60 min.

Water/acetonitrile mixture (1.5 mL) was added through a septum to argon-purged vial containing **5** (36.9 mg, 0.10 mmol), **2d** (53.8 mg, 0.12 mmol), and CuI (2.1 mg, 0.01 mol). In a separate vial Pd(OAc)₂ (1.1 mg, 0.005 mmol) and TPPTS (14.2 mg, 0.025 mmol) were combined under argon with 0.5 mL of H₂O-CH₃CN (2:1). After dissolution of the solids, the catalyst solution was added to the reaction mixture followed by addition of EtN(*i*-Pr)₂ (174 μL, 1.0 mmol). Reaction mixture was stirred under argon at 75 °C for 60 min. Mixture was then concentrated and purified by column chromatography twice, first with EtOAc-CH₃OH (5:2) and again with CHCl₃-CH₃OH (10:1-10:4 gradient) and dried *in vacuo* to give 17.7 mg (26 %) of **9d** as yellowish oil. λ_{max} (MeOH)/nm 202 (ε/dm³ mol⁻¹ cm⁻¹ 11300), 240 (ε/dm³ mol⁻¹ cm⁻¹ 4900), 327 (ε/dm³ mol⁻¹ cm⁻¹ 2200); NMR. ESI MS⁺: Found: 694.4 [M+Na], 792.1 [M+K], 1365.4 [2M+Na]. HRMS (ES⁻): found m/z: 670.3704 (C₃₆H₅₂N₃O₉ requires 670.3709).

Synthesis of modified dNTPs – Sonogashira cross-coupling – General procedure:

Water/acetonitrile mixture (1.5 mL) was added through a septum to argon-purged vial containing halogenated nucleoside triphosphate **dA^ITP** or **dC^ITP**, acetylene **2** (1.5 eqv.), and CuI (10 mol %). In a separate vial Pd(OAc)₂ (5 mmol %) and TPPTS (5 eqv. to Pd) were combined under argon with 0.5 mL of H₂O-CH₃CN. After dissolution of the solids, the catalyst solution was added to the reaction mixture followed by addition of EtN(*i*-Pr)₂ (10 eqv.). Reaction mixture was stirred under argon at 75 °C for 45 min. The product was isolated from the crude reaction mixture by HPLC on a C18 column using two-step linear gradient from 0.1 M TEAB (triethylammonium bicarbonate) in H₂O to 0.1 M TEAB in H₂O/MeOH (1:1) and from 0.1 M TEAB in H₂O/MeOH (1:1) to MeOH as an eluent. Several co-distillations from water and conversion to sodium salt form (Dowex 50WX8 in Na⁺ cycle) followed by freeze drying gave products as white solids.

**7-{{(3 α ,7 α ,12 α -trihydroxy-24-oxo-5 β -cholan-24-yl)amino}prop-1-yn-1-yl}-7-deaza-2'-
deoxyadenosinetriphosphate (dA^{CA}TP)**

Prepared from dA^ITP and **2d**, yield 44 %.

MS (ES⁻): found m/z: 465.8 ([M-2H]²⁻); HRMS (ES⁻): found m/z: 465.6470 (C₃₈H₅₆N₅O₁₆P₃, z=2 requires 465.6473). NMR: Tables S1 and S2.

**7-{{(3 α ,12 α -dihydroxy-24-oxo-5 β -cholan-24-yl)amino}prop-1-yn-1-yl}-7-deaza-2'-
deoxyadenosinetriphosphate (dA^{DCA}TP)**

Prepared from dA^ITP and **2d**, yield 57 %.

NMR; MS (ES⁻): found m/z: 457.8 ([M-2H]²⁻); HRMS (ES⁻): found m/z: 457.6502 (C₃₈H₅₆N₅O₁₅P₃, z=2 requires 454.1393). NMR: Tables S1 and S2.

**5-{{(3 α ,7 α ,12 α -trihydroxy-24-oxo-5 β -cholan-24-yl)amino}prop-1-yn-1-yl}-2'-
deoxycytidinetriphosphate (dC^{CA}TP)**

Prepared from dA^ITP and **2d**, yield 32 %.

NMR; MS (ES⁻): found m/z: 414.3 ([M-PO₃-2H]²⁻), 454.3 ([M-2H]²⁻); HRMS (ES⁻): found m/z: 454.1385 (C₃₆H₅₅N₄O₁₇P₃, z=2 requires 454.1393). NMR: Tables S3 and S4.

**5-{{(3 α ,12 α -dihydroxy-24-oxo-5 β -cholan-24-yl)amino}prop-1-yn-1-yl}-2'-
deoxycytidinetriphosphate (dC^{DCA}TP)**

Prepared from dA^ITP and **2d**, yield 53 %.

MS (ES⁻): found m/z: 406.3 ([M-PO₃-2H]²⁻), 446.3 ([M-2H]²⁻); HRMS (ES⁻): found m/z: 446.1413 (C₃₆H₅₅N₄O₁₆P₃, z=2 requires 446.1418). NMR: Tables S3 and S4.

Primer extension, purification and analysis of the PEX products

Materials: Synthetic ONs were purchased from either VBC genomics (Austria) or from Sigma

Aldrich. Primer: 5'-CAT GGG CGG CAT GGG-3'; Templates: 5'-CTA GCA TGA GCT

CAG TCC CAT GCC GCC CAT G-3' (temp^{md16}), 5'-CCC **GCC CAT GCC GCC CAT G-3'**

(temp^{1C}), 5'-CCC TCC CAT GCC GCC CAT G-3' (temp^{1A}), 5'-GCG ACG AAG AGC TTC

CCA TGC CGC CCA TG-3' (temp^{AA}), 5'-TTA TAT TTA TAC CCA TGC CGC CCA TG-3'

(temp^{3A}), 5'-TAT ATA TAT ATC CCA TGC CGC CCA TG-3' (temp^{rep}) (segments forming a

duplex with the primer are underlined, the replicated segments are in bold). Template temp^{1C} used

in experiment involving the DBstv magnetoseparation procedure was biotinylated at its 5' ends.

Dynabeads M-270 streptavidin (DBstv) were obtained from Dynal A.S. (Norway), DyNAzyme II and Phusion DNA Polymerases from Finnzymes (Finland), Pwo DNA Polymerase from PeqLab (Germany), unmodified nucleoside triphosphates (dATP, dTTP, dCTP, and dGTP) from Fermentas (USA), Vent (exo-) DNA Polymerase and T4 polynucleotide kinase from New England Biolabs (Great Britain) and γ -³²P-ATP from Izotop, Institute of isotopes Co, Ltd. (Hungary).

Primer extension experiments: The reaction mixture (20 μ L) contained DNA polymerase (2 U), dNTPs (either natural or modified, 200 μ M; composition of the dNTP is specified in the text and Figure legends for individual experiments), primer (150 nM) and ON template (225 nM) in the reaction buffer. For polyacrylamide gel electrophoresis (PAGE) experiments, the primer was labeled using [γ ³²P]-ATP according to standard techniques. Reaction mixtures were incubated at 60 °C for 30 min and at 95 °C for 5 min in a thermal cycler and were stopped by addition of stop solution (40 μ L, 80 % [v/v] formamide, 20 mM EDTA, 0.025% [w/v] bromophenol blue, 0.025% [w/v] xylene cyanol). Reaction mixture was subjected to gel electrophoresis in 12.5 % denaturing polyacrylamide gel containing 1 \times TBE buffer (ph 8) and 7 % urea at 50-60 W for ~60 min. Gels were dried and phosphoroimaged.

Polymerase chain reactions: The PCR reaction mixture (20 μ L) contained DNA polymerase Phusion (2 U, Finnzymes, Finland), dNTPs (either natural (200 μ M) or modified (600 μ M)), DMSO (5 %), formamide (0.25 %), betaine (37.5 mM) and tetramethylammoniumchloride (2.5 mM) primers LT25TH (400 nM, 5'-CAAGGACAAAATACCTGTATTCCTT-3') and L20- (400 nM, 5'-GACATCATGAGAGACATCGC-3'), template (25 nM, 5'-GACATCATGAGAGACATCGCCTCTGGGCTAATAGGACTACTTCTAATCTGTAAGAGCAGATCCCTGGACAGGCAAGGAATACAGGTATTTTGTCTTG-3'), in the Phusion reaction buffer HF 5 \times supplied by the manufacturer. 30 PCR cycles were run under the following conditions: denaturation for 1 min at 94 °C, annealing for 1 min at 55 °C, extension for 1.5 min at 72 °C, followed by final extension step of 5 min at 72 °C. PCR products were analyzed on a 2 % agarose gel in 0.5 \times TBE buffer, followed by staining with GelRedTM.

Thermal denaturation studies: Double stranded ONs were prepared by PEX-reaction in 500 μ L scale using primer (2 μ M), template (2 μ M), Phusion DNA polymerase (0.2 U), and dNTPs (200 μ M) in the reaction buffer. The PEX-products were purified using QIAquick Nucleotide Removal Kit Protocol (Qiagen). The melting temperature of oligonucleotides containing modified base or bases hybridized with natural DNA template were measured. The melting temperature of the control

unmodified duplex was also determined in each case. The DNA duplexes were dissolved in 160 μL of phosphate buffer (10mM) and 1M NaCl (pH 7) and further diluted to final duplex concentrations of $0.73 \pm 0.3 \mu\text{M}$ with the buffer. Melting curves were recorded on a Cary 100 bio UV/Vis instrument with temperature controller (Varian). Melting temperatures (T_m values in $^\circ\text{C}$) were obtained by plotting temperature versus absorbance and by applying a sigmoidal curve fit and results are averages of 4-6 measurements.

MALDI-TOF experiment (ssDNA)

The reaction mixture (200 μL) of Phusion DNA Polymerase (Finnzymes, 10 units, 5 μL), dNTP (either natural or functionalized, 4mM, 10 μL), primer (10 μM , 80 μL , 3'-GGGTACGGCGGGTAC-5'), and 19-mer biotinylated template (10 μM , 40 μL , temp¹³C-bio: 5'-CCCGCCCATGCCGCCCATG-3') in Phusion reaction buffer HF 5 \times (40 μL) supplied by the manufacturer. Reaction mixtures were incubated for 30 min at 60 $^\circ\text{C}$ in a thermal cycler. The separation on magnetic beads (100 μM , Sigma-Aldrich) were carried out according to standard techniques. As matrix for MALDI-TOF measurement was used a mixture of 3-hydroxypicolinic acid (HPA)/picolinic acid (PA)/ammonium tartrate in ratio 9/1/1 respectively. Then 2 μL of the matrix and 0.5 μL of the sample were mixed on target by use of anchor-chip desk. The crystallized spots were washed once by 0.1% formic acid and once by water. The acceleration tension in reflectron mode was 19.5kV and range of measurement 3–13kDa.

- a) Mass (ssDNA: natural dNTPs): calculated: 5950.9 Da; found: 5953.9 Da; $\Delta = 3$ (Figure S1)
- b) Mass (ssDNA: **dC^{CA}TP**, dGTP, dATP, TTP): calculated: 6394.5 Da; found: 6394.3 Da; $\Delta = 0.2$ (Figure S1)
- c) Mass (ssDNA: **dC^{DCA}TP**, dGTP, dATP, TTP): calculated: 6378.5 Da; found: 6379.2 Da; $\Delta = 0.7$ (Figure S1)




Figure S1: MALDI-TOF spectra of PEX products with temp¹³C-bio and with a) +: natural dNTPs; b) C^{CA}: dC^{CA}-TP, dTTP, dATP, dGTP; c) C^{DCA}: dC^{DCA}-TP, dTTP, dATP, dGTP

Sequence analysis of PCR products

The products of PCR with natural dNTPs and with dC^{CA}-TP were purified by QIAquick PCR purification kit (Qiagen). Concentrations of products were measured on Nanodrop 1000 Spectrophotometer (+: 6.9 ng/ μ l ; C^{CA}: 3.3 ng/ μ l) . 0.5 μ l of natural DNA + and 1 μ l of DNA containing dC^{CA} was used as template for new PCR reaction using natural dNTPs employing forenamed procedure (Figure S2). 3 ng of DNA were mixed with L20- (230 nM) and completed to 14 μ l. Sequence analysis (Figure S3) were done by Seqlab (Charles University, Prague).





Figure S2: Agarose gel electrophoresis analysis of PCR products prepared from natural dNTPs and templates purified from previous PCR (+: natural template, C^{CA}: template containing dC^{CA} instead of natural dC)

98-mer template:

5'GACATCATGAGAGACATCGCCTCTGGGCTAATAGGACTACTTCTAATCTGTAAGAGCAGATCCCTGGACAGGCAAGGAATA
CAGGTATTTTGCCTTG 3'

File: HAC-pozL20_E12.ab1 Run Ended: Nov 11, 2009, 23:46:03 Signal G:808 A:477 T:373 C:279 Com
Sample: HAC-pozL20 Lane: 1 Base spacing 14.46 74 bases in 1019 scans Page
10 20 30 40 50 60
GT AATGG CATC TTC TA TCTGT A G AG CAG ATCCC T G G ACAG G CAAGG AATACA GGTATTTT GTCCTGG

a



File: HAC-C1L20_G12.scf Run Ended: Nov 11, 2009, 23:46:03 Signal G:1007 A:581 T:504 C:357 Comment:
Sample: HAC-C1L20 Lane: 3 Base spacing 14.46 82 bases in 1073 scans Page 1 of 1
10 20 30 40 50 60 70
GT AATGG AATC TTC TAG TCTGT AAG AG CAG ATCCC T G G ACAG G CAAGG AATACA GGTATTTT GTCCTTA

b




Figure S3: Sequence analysis of DNA prepared from natural dNTPs and natural (a) or modified template containing dC^{CA} instead of natural dC (b). Determined sequence is red in original template and in the frames in the graphs of sequence analysis.

Supplementary results – PAGE of PEX:




Figure S4. Denaturing PAGE analysis of PEX products synthesized on a temp^{md16} with Vent (exo-) (a) and DyNAzyme (b) DNA polymerases. 5-³²P-end-labeled primer-template was incubated with different combinations of natural and functionalized dNTPs. P=Primer; +: natural dNTPs; -A: dTTP, dCTP, dGTP; -C: dATP, dTTP, dGTP; A^{CA}: **dA^{CA}TP**, dTTP, dCTP, dGTP; A^{DCA}: **dA^{DCA}TP**, dTTP, dCTP, dGTP; C^{CA}: **dC^{CA}TP**, dATP, dTTP, dGTP; C^{DCA}: **dC^{DCA}TP**, dATP, dTTP, dGTP.




Figure S5. Denaturing PAGE analysis of PEX products synthesized on a temp^{md16} with Pwo DNA polymerase. 5-³²P-end-labeled primer-template was incubated with different combinations of natural and functionalized dNTPs. P=Primer; +: natural dNTPs; -A: dTTP, dCTP, dGTP; -C: dATP, dTTP, dGTP; A^{CA}: **dA^{CA}TP**, dTTP, dCTP, dGTP; A^{DCA}: **dA^{DCA}TP**, dTTP, dCTP, dGTP; C^{CA}: **dC^{CA}TP**, dATP, dTTP, dGTP; C^{DCA}: **dC^{DCA}TP**, dATP, dTTP, dGTP.




Figure S6. Denaturing PAGE analysis of PEX products synthesized on a temp^{3A} (a) and temp^{rep} (b) with Phusion DNA polymerase. 5- ^{32}P -end-labeled primer-template was incubated with different combinations of natural and functionalized dNTPs. P=Primer; +: natural dNTPs; -A: dTTP, dCTP, dGTP; A^{CA} : $\text{dA}^{\text{CA}}\text{TP}$, dTTP, dCTP, dGTP; A^{DCA} : $\text{dA}^{\text{DCA}}\text{TP}$, dTTP, dCTP, dGTP.

References:

- 1) N. G. Aher, V. S. Pore, and S. P. Patil, *Tetrahedron*, 2007, **63**, 12927-12934.
- 2) P. Čapek, H. Cahová, R. Pohl, M. Hocek, C. Gloeckner, A. Marx, *Chem. Eur. J.* **2007**, *13*, 6196-6203. H. Cahová, L. Havran, P. Brázdilová, H. Pivoňková, R. Pohl, M. Fojta, M. Hocek, *Angew. Chem. Int. Ed.* **2008**, *47*, 2059-2062.
- 3) N. S. Vatmurge, B. G. Hazra, V. S. Pore, F. Shirazi, P. S. Chavan, and M. V. Deshpande, *Bioorg. Med. Chem. Lett.*, 2008, **18**, 2043-2047.

Table S1. ¹H NMR of 7-deazaadenine - bile acids conjugates

Proton	Compound						
	6d 500.0 MHz CD ₃ OD	6e 500.0 MHz CD ₃ OD	6a 500.0 MHz CD ₃ OD	6b 600.1 MHz CD ₃ OD	6c 600.1 MHz CD ₃ OD	dA^{CA}TP 600.1 MHz D ₂ O ^a	dA^{DCA}TP 600.1 MHz D ₂ O ^a
1''α	1.77	1.73 dt (14.2, 3.2)	1.77 dt (14.4, 3.1)	1.76	1.80 dt (14.3, 3.6)	1.65 dt (14.6, 3.5)	1.60
1''β	0.96 td (14.2, 3.4)	0.96 td (14.2, 3.4)	0.95 td (14.4, 3.5)	0.95 td (14.2, 3.5)	0.96 td (14.3, 3.5)	0.95 td (14.6, 3.5)	0.88
2''α	1.40	1.40	1.41	1.39	1.29	1.23	1.23
2''β	1.58	1.59	1.58	1.59	1.58	1.59	1.58
3''β	3.36 tt (11.5, 4.1)	3.51 tt (11.2, 4.6)	3.35 tt (11.3, 4.5)	3.51 tt (11.2, 4.5)	3.35 tt (11.1, 4.1)	3.46 tt (11.1, 4.4)	3.58 bm
4''α	2.25	1.78	2.25 td (13.2, 11.3)	1.76	2.23 td (13.3, 11.3)	1.93 td (12.9, 11.7)	1.65
4''β	1.63	1.44	1.63	1.44	1.63	1.64	1.42
5''β	1.35	1.38	1.35	1.37	1.33	1.38	1.30
6''α	1.50	1.25	1.48 dt (14.7, 2.1)	1.24	1.49 dt (14.8, 2.3)	1.46 dt (15.0, 2.8)	1.16
6''β	1.92	1.86	1.92 ddd (14.7, 5.7, 3.1)	1.87	1.92 ddd (14.8, 5.5, 3.5)	1.88	1.69
7''α		1.11 qd 13.8, 3.7)		1.10 qd (13.8, 3.5)			0.93
7''β	3.71 q (3.2)	1.35	3.70 q (3.1)	1.34	3.70 q (3.0)	3.51 q (2.8)	1.19
8''β	1.39	1.33	1.38	1.31	1.37	0.89 dt (11.7, 2.8)	0.91
9''α	2.19	1.84	2.19 td (12.5, 4.6)	1.85	1.84	1.88	1.25
11''α	1.52	1.44	1.51	1.43	1.42	1.33	1.24
11''β	1.45	1.44	1.44	1.43	1.19 ddd (13.2, 12.4, 3.7)	1.21	1.14
12''α					1.12 ddd (13.4, 12.6, 4.0)		
12''β	3.88 t (2.9)	3.89 t (3.0)	3.86 t (3.1)	3.87 t (2.9)	1.91	3.81 t (2.9)	3.79 b
14''α	1.89	1.53	1.90	1.53	1.37	1.53	1.29
15''α	0.79 qd (11.6, 5.7)	0.80 qd (11.9, 5.8)	0.77 qd (12.2, 5.9)	0.79 qd (12.1, 6.1)	0.79 qd (11.8, 6.4)	0.01	0.28
15''β	1.59	1.47	1.59	1.46	1.59	1.53	1.30
16''α	1.82	1.81	1.82	1.81	1.84	1.75	1.74
16''β	1.24	1.25	1.24	1.24	1.27	1.05	1.05
17''α	1.80	1.78	1.79	1.77	1.10 q (9.6)	1.52	1.54
18''	0.51 s	0.52 s	0.47 s	0.48 s	0.46 s	0.06 s	0.18 s
19''	0.87 s	0.89 s	0.87 s	0.88 s	0.88 s	0.74 s	0.72 s
20''	1.39	1.40	1.39	1.38	1.43	1.22	1.26
21''	1.02 d (6.5)	1.01 d (6.5)	1.09 d (6.4)	0.99 d (6.5)	0.94 d (6.5)	0.92 d (6.2)	0.93 bd (5.0)
22''a	1.86	1.85	1.89	1.91	1.91	1.81 td (12.4)	1.77
22''b	1.29	1.31	1.31	1.32	1.98	1.19	1.26
23''a	2.27	2.29 dd (13.7, 8.4, 5.1)	2.44 ddd (14.9, 7.6, 5.1)	2.41 ddd (15.0, 7.9, 5.2)	2.43 ddd (14.9, 7.8, 5.2)	2.31 dt (13.5, 4.6)	2.31 bm
23''b	2.19	2.19 dt (13.7, 8.3)	2.36 ddd (14.9, 9.1, 7.3)	2.36 ddd (15.0, 8.9, 7.5)	2.35 ddd (14.9, 8.9, 7.4)	2.27 td (13.5, 12.4, 3.5)	2.23 bm
25''a	4.17 d (17.6)	4.16 d (17.6)	4.94 d (15.8)	4.93 d (15.8)	4.94 d (15.8)	4.22 d (17.8)	4.15 d (17.8)
25''b	4.10 d (17.6)	4.11 d (17.6)	4.90 d (15.8)	4.90 d (15.8)	4.90 d (15.8)	4.08 d (17.8)	4.10 d (17.8)
2	8.09 s	8.09 s	8.09 s	8.23 bs	8.09 bs	8.12 s	8.11 s
8	7.59 s	7.57 s	7.66 s	7.66 s	7.65 s	7.74 s	7.67
1'	6.47 dd (8.1, 6.0)	6.46 dd (8.3, 5.9)	6.47 dd (8.2, 5.9)	6.47 dd (8.2, 5.9)	6.46 dd (8.2, 6.0)	6.53 dd (7.9, 6.1)	6.52 bdd (8.0, 5.8)
2'a	2.61 ddd (13.4, 8.2, 5.8)	2.62 ddd (13.4, 8.3, 5.9)	2.61 ddd (13.4, 8.2, 5.8)	2.62 ddd (13.4, 8.2, 5.9)	2.61 ddd (13.6, 8.2, 5.9)	2.63 ddd (14.0, 7.9, 6.2)	2.63 bddd (13.6, 8.0, 5.8)
2'b	2.31 ddd (13.4, 6.0, 2.6)	2.31 ddd (13.4, 5.9, 2.6)	2.32 ddd (13.4, 5.9, 2.6)	2.33 ddd (13.4, 5.9, 2.5)	2.32 ddd (13.6, 6.0, 2.5)	2.40 ddd (14.0, 6.1, 3.1)	2.43 bddd (13.6, 5.8, 3.0)
3'	4.51 dt (5.8, 2.6)	4.51 dt (5.9, 2.6)	4.51 dt (5.8, 2.6)	4.51 dt (5.9, 2.5)	4.51 dt (5.9, 2.5)	4.74 ddd (6.2, 3.1, 2.7)	4.72 bdt (5.8, 3.1)
4'	4.00 td (3.4, 2.6)	4.01 td (3.4, 2.6)	4.01 td (3.4, 2.6)	4.01 td (3.3, 2.5)	4.01 td (3.3, 2.5)	4.21 tdd (3.7, 2.7, 1.5)	4.21 bm
5'a	3.79 dd (12.1, 3.4)	3.79 dd (12.2, 3.4)	3.80 dd (12.1, 3.4)	3.80 dd (12.1, 3.3)	3.80 dd (12.1, 3.3)	4.19 ddd (10.7, 6.2, 3.7)	4.16 bm
5'b	3.72 dd (12.1, 3.4)	3.72 dd (12.2, 3.4)	3.72 dd (12.1, 3.4)	3.72 dd (12.1, 3.3)	3.72 dd (12.1, 3.3)	4.11 ddd (10.7, 4.9, 3.7)	4.11 bm

^a In phosphate buffer, pD = 7.1, referenced to 1,4-dioxane signal (3.75 ppm)

Table S2. ^{13}C NMR of 7-deazaadenine - bile acids conjugates

Carbon	Compound						
	6d 125.7 MHz CD_3OD	6e 125.7 MHz CD_3OD	6a 125.7 MHz CD_3OD	6b 150.9 MHz CD_3OD	6c 150.9 MHz CD_3OD	dA^{CA}TP 150.9 MHz D_2O^a	dA^{DCA}TP 150.9 MHz D_2O^a
1''	36.44	36.39	36.44	36.40	36.51	37.10	37.30
2''	31.14	31.03	31.14	31.04	31.32	31.83	31.75
3''	72.84	73.09	72.85	73.07	72.83	74.32	74.21
4''	40.42	37.16	40.42	37.17	40.44	40.99	37.81
5''	43.14	43.58	43.15	43.59	43.13	43.47	44.32
6''	35.81	28.38	35.80	28.39	35.85	36.41	29.55
7''	68.99	27.40	68.99	27.40	69.02	71.09	28.63
8''	40.89	37.34	40.90	37.34	40.66	41.77	38.41
9''	27.79	34.73	27.78	34.74	33.94	28.76	35.87
10''	35.86	35.27	35.86	35.28	36.19	36.92	36.40
11''	29.47	29.80	29.46	29.79	21.69	29.90	30.37
12''	73.99	74.00	73.94	73.96	40.91	75.75	75.87
13''	47.42	47.49	47.42	47.50	43.60	48.58	48.66
14''	42.86	49.29	42.85	48.86	51.42	43.67	49.98
15''	24.13	24.78	24.14	24.80	24.55	25.28	26.13
16''	28.76	28.72	28.72	28.69	29.26	30.03	30.11
17''	48.08	48.14	48.12	48.20	57.37	49.42	49.29
18''	12.90	13.11	12.84	13.05	12.01	14.31	14.76
19''	23.19	23.72	23.19	23.72	23.41	24.35	25.11
20''	36.43	36.39	36.38	36.35	36.39	36.46	36.92
21''	17.75	17.69	17.52	17.48	18.72	19.56	19.54
22''	33.37	33.34	32.54	32.49	32.54	34.65	34.55
23''	34.03	33.99	32.18	32.15	32.14	35.94	35.59
24''	177.10	177.08	175.68	175.68	175.65	180.24	180.17
25''	30.63	30.62	53.74	53.75	53.76	32.22	32.36
26''	89.89	89.74	88.09	88.07	88.05	91.89	91.75
27''	75.79	75.88	80.14	80.14	80.17	77.36	77.35
2	152.72	153.17	153.32	153.22	153.31	154.88	154.70
4	149.75	149.84	149.98	150.02	149.99	151.12	151.09
5	104.90	104.97	104.99	104.70	105.02	106.22	106.10
6	158.88	159.19	159.21	159.24	159.23	160.33	160.03
7	97.21	97.07	96.30	96.55	96.35	99.34	99.35
8	128.07	127.98	128.84	128.66	128.84	129.65	129.23
1'	86.78	86.84	86.91	86.92	86.94	85.71	85.67
2'	41.70	41.66	41.76	41.76	41.76	41.83	41.61
3'	73.08	72.51	73.08	72.52	73.08	73.91	73.83
4'	89.29	89.28	89.34	89.35	89.35	88.02 d (8.9)	87.92 d (9.1)
5'	63.64	63.66	63.64	63.64	63.65	68.24 d (5.9)	68.30 d (5.3)

^a In phosphate buffer, pD = 7.1, referenced to 1,4-dioxane signal (69.3 ppm)

dA^{CA}TP ^{31}P NMR (202.3 MHz, D_2O , pD = 7.1, ref (phosphate buffer) = 2.35 ppm): -21.19 (t, $J = 20$, P β); -9.92 (d, $J = 20$, P α); -7.29 (d, $J = 20$, P γ).

dA^{DCA}TP ^{31}P NMR (202.3 MHz, D_2O , pD = 7.1, ref (phosphate buffer) = 2.35 ppm): -21.03 (t, $J = 19$, P β); -9.77 (d, $J = 19$, P α); -7.37 (d, $J = 19$, P γ).

Table S3. ¹H NMR of cytosine - bile acids conjugates

Proton	Compound						
	7d 500.0 MHz CD ₃ OD	7e 499.8 MHz CD ₃ OD	7a 500.0 MHz CD ₃ OD	7b 500.0 MHz CD ₃ OD	7c 500.0 MHz CD ₃ OD	dC ^{CA} TP 499.8 MHz D ₂ O ^a	dC ^{DCA} TP 499.8 MHz D ₂ O ^a
1"α	1.80 dt (14.0, 3.2)	1.77 dt (14.1, 3.2)	1.80 dt (14.2, 3.3)	1.76 dt (14.2, 3.5)	1.84	1.76 dt (14.4, 3.1)	1.72
1"β	0.98 td (14.0, 3.4)	0.98 td (14.1, 3.5)	0.98 td (14.2, 3.5)	0.97 td (14.2, 3.5)	0.98 td (14.1, 3.2)	0.99 td (14.4, 3.2)	0.97 td (14.4, 3.4)
2"α	1.41	1.40	1.41	1.41	1.33	1.26	1.28
2"β	1.59	1.59	1.59	1.59	1.61	1.62	1.60
3"β	3.37 tt (11.0, 4.3)	3.52 tt (11.0, 4.7)	3.37 tt (11.1, 4.4)	3.52 tt (11.2, 4.7)	3.37 tt (11.2, 4.5)	3.49 tt (11.0, 4.5)	3.63 tt (10.9, 4.7)
4"α	2.26	1.79	2.27 td (13.2, 11.5)	1.80	2.25 td (13.3, 11.5)	1.99	1.72
4"β	1.64	1.44	1.65	1.45	1.65	1.67	1.47
5"β	1.37	1.38	1.37	1.38	1.37	1.43	1.40
6"α	1.52	1.26	1.52	1.26	1.52 dt (14.8, 2.3)	1.46	1.23
6"β	1.95	1.88	1.96	1.89	1.96	1.96	1.81
7"α		1.14 qd (13.4, 4.2)		1.15 qd (12.7, 4.1)			1.03
7"β	3.78 q (2.9)	1.42	3.78 q (3.0)	1.42	3.78 q (2.8)	3.75	1.29
8"β	1.51	1.46	1.52	1.47	1.48	1.43	1.31
9"α	2.23	1.88	2.13 dt (13.6, 6.5)	1.89	1.86	1.98	1.66
11"α	1.56	1.50	1.56	1.50	1.47	1.52	1.44
11"β	1.56	1.50	1.56	1.50	1.19	1.52	1.44
12"α					1.18 td (12.0, 4.0)		
12"β	3.93 t (3.2)	3.94 t (3.0)	3.93 t (3.1)	3.94 t (3.0)	1.98	3.99 t (2.9)	3.98 t (2.8)
14"α	1.96	1.59	1.97	1.59	1.48	1.68	1.39
15"α	1.03 qd (11.8, 5.5)	1.03	1.05 qd (12.1, 5.7)	1.02	1.04 qd (11.7, 6.3)	0.68 qd (11.9, 6.2)	0.64 qd (11.9, 6.5)
15"β	1.71	1.58	1.71	1.58	1.71	1.53	1.48
16"α	1.87	1.85	1.86	1.85	1.90	1.83	1.81
16"β	1.26	1.26	1.28	1.26	1.33	1.12	1.09
17"α	1.84	1.82	1.84	1.82	1.16 q (9.8)	1.60	1.58
18"	0.66 s	0.66 s	0.66 s	0.66 s	0.64 s	0.49 s	0.49 s
19"	0.91 s	0.92 s	0.91 s	0.92 s	0.92 s	0.88 s	0.88 s
20"	1.40	1.40	1.41	1.40	1.44	1.30	1.27
21"	1.02 d (6.5)	1.02 d (6.4)	1.01 d (6.4)	1.00 d (6.5)	0.96 d (6.6)	0.98 d (6.2)	0.96 d (6.0)
22"a	1.83	1.81	1.86	1.84	1.86	1.81	1.80
22"b	1.31	1.33	1.34	1.33	1.31	1.23	1.25
23"a	2.28	2.28 ddd (13.8, 9.2, 5.2)	2.44 ddd (15.3, 8.6, 5.2)	2.44 ddd (15.3, 8.8, 5.2)	2.43 ddd (15.3, 8.5, 5.2)	2.29 dd (8.6, 4.6)	2.28 dd (9.1, 4.3)
23"b	2.18	2.16 ddd (13.8, 8.8, 7.6)	2.34 dt (15.3, 7.9)	2.33 dt (15.3, 8.0)	2.33 dt (15.3, 8.2)		
25"a	4.16 d (17.7)	4.15 d (17.7)	4.94 d (15.9)	4.94 d (15.9)	4.94 d (15.9)	4.24 d (17.9)	4.22 d (17.8)
25"b	4.11 d (17.7)	4.12 d (17.7)	4.89 d (15.9)	4.89 d (15.9)	4.89 d (15.9)	4.05 bd (17.9)	4.06 d (17.8)
6	8.31 s	8.31 s	8.40 s	8.40 s	8.40	8.18	8.18
1'	6.20 dd (6.4, 6.1)	6.20 t (6.2)	6.19 t (6.2)	6.20 t (6.3)	6.20 t (6.3)	6.21 t (6.2)	6.22 t (6.3)
2'a	2.39 ddd (13.6, 6.1, 3.8)	2.39 ddd (13.6, 6.2, 3.9)	2.39 ddd (13.6, 6.2, 4.0)	2.39 ddd (13.6, 6.3, 3.9)	2.39 ddd (13.6, 6.3, 3.6)	2.41 bm	2.43 ddd (14.1, 6.3, 4.6)
2'b	2.12 dt (13.6, 6.4)	2.12 dt (13.6, 6.2)	2.24 dt (13.6, 6.2)	2.13 dt (13.6, 6.3)	2.13 dt (13.6, 6.3)	2.25 bm	2.26 dt (14.1, 6.3)
3'	4.36 dt (6.4, 3.8)	4.36 dt (6.2, 3.9)	4.36 dt (6.2, 4.0)	4.37 dt (6.3, 3.9)	4.37 dt (6.3, 3.6)	4.62 bm	4.61 dt (6.3, 4.6)
4'	3.95 ddd (3.8, 3.6, 3.2)	3.95 ddd (3.9, 3.6, 3.2)	3.95 ddd (4.0, 3.5, 3.1)	3.95 ddd (3.9, 3.5, 3.2)	3.95 td (3.6, 3.1)	4.16 bm	4.17 bm
5'a	3.81 dd (12.1, 3.2)	3.81 dd (12.0, 3.2)	3.83 dd (12.0, 3.1)	3.83 dd (12.1, 3.2)	3.83 dd (12.1, 3.1)	4.25 bm	4.23 bm
5'b	3.73 dd (12.1, 3.6)	3.73 dd (12.0, 3.6)	3.74 dd (12.0, 3.5)	3.74 dd (12.1, 3.5)	3.74 dd (12.1, 3.6)	4.20 bm	4.20 bm

^a In phosphate buffer, pD = 7.1, referenced to 1,4-dioxane signal (3.75 ppm)

Table S4. ^{13}C NMR of cytosine - bile acids conjugates

Carbon	Compound						
	7d	7e	7a	7b	7c	dC^{CA}TP	dC^{DCA}TP
	125.7 MHz	125.7 MHz	125.7 MHz	125.7 MHz	125.7 MHz	125.7 MHz	125.7 MHz
	CD_3OD	CD_3OD	CD_3OD	CD_3OD	CD_3OD	D_2O^a	D_2O^a
1''	36.46	36.42	36.46	36.40	36.52	37.20	37.29
2''	31.14	31.07	31.15	31.05	31.32	31.91	31.82
3''	72.86	72.53	72.86	72.52	72.83	74.41	74.37
4''	40.43	37.20	40.43	37.17	40.44	41.06	37.77
5''	43.15	43.62	43.15	43.59	43.13	43.57	44.39
6''	35.84	28.40	35.82	28.39	35.86	36.48	29.53
7''	69.07	27.46	69.07	27.45	69.06	71.23	28.60
8''	40.94	37.43	40.95	37.41	40.70	41.83	38.43
9''	27.84	34.81	27.84	34.78	34.01	29.01	36.04
10''	35.89	35.30	35.89	35.29	36.20	36.97	36.41
11''	29.53	29.89	29.53	29.87	21.75	30.13	30.49
12''	74.06	74.04	74.01	74.00	40.98	75.91	76.21
13''	47.49	47.57	47.50	47.56	43.68	48.92	48.92
14''	42.98	49.28	42.98	49.26	51.52	44.19	50.43
15''	24.29	24.91	24.29	24.92	24.67	25.76	26.42
16''	28.76	28.70	28.73	28.68	29.29	30.16	30.22
17''	48.03	48.12	48.07	48.14	57.30	49.52	49.58
18''	13.05	13.25	13.05	13.24	12.22	14.72	14.98
19''	23.17	23.72	23.17	23.71	23.40	24.39	25.04
20''	36.46	36.58	36.54	36.50	36.55	36.74	36.74
21''	17.74	17.70	17.54	17.49	18.74	19.59	19.56
22''	33.24	33.20	32.30	32.25	32.29	34.71	34.65
23''	33.93	33.92	32.03	32.00	31.99	35.89	35.85
24''	176.92	176.85	175.45	175.37	175.36	180.34	180.36
25''	30.54	30.54	53.51	53.51	53.53	32.15	32.15
26''	92.88	92.86	91.22	91.21	91.20	95.40	95.34
27''	74.46	74.47	78.40	78.36	78.39	75.52	75.48
2	156.70	156.71	156.65	156.69	156.68	158.44	158.51
4	166.57	166.56	166.50	166.48	166.48	168.00	168.01
5	92.38	92.36	91.64	91.67	91.66	95.40	85.15
6	145.85	145.83	146.76	146.74	146.75	148.01	148.01
1'	87.97	87.98	88.03	88.02	88.03	88.85	88.86
2'	42.43	42.44	42.48	42.48	42.47	42.38	42.36
3'	71.80	71.82	71.71	71.75	71.73	72.77	72.77
4'	89.08	89.11	89.10	89.14	89.12	88.24 br	88.19 d (9.0)
5'	62.48	62.52	62.40	62.42	62.41	67.70 br	67.71 d (4.7)

^a In phosphate buffer, pD = 7.1, referenced to 1,4-dioxane signal (69.3 ppm)

dC^{CA}TP ^{31}P NMR (202.3 MHz, D_2O , pD = 7.1, ref (phosphate buffer) = 2.35 ppm): -21.14 (br, P β); -10.34 (br, P α); -6.82 (br, P γ).

dC^{DCA}TP ^{31}P NMR (202.3 MHz, D_2O , pD = 7.1, ref (phosphate buffer) = 2.35 ppm): -21.34 (bdd, $J = 19, 15$, P β); -10.37 (d, $J = 19$, P α); -7.23 (bd, $J = 15$, P γ).

Table S5. ^1H NMR of uracil - bile acids conjugates

Proton	9d^a	8e
	499.8 MHz DMSO- <i>d</i> ₆	500.0 MHz CD ₃ OD
1'' α	1.64	1.77 dt (14.2, 3.4)
1'' β	0.84	0.98 td (14.2, 3.5)
2'' α	1.26	1.41
2'' β	1.43	1.60
3'' β	3.18	3.52 tt (11.1, 4.6)
4'' α	2.21	1.80
4'' β	1.44	1.46
5'' β	1.24	1.39
6'' α	1.36	1.27
6'' β	1.78	1.88
7'' α		1.17 qd (13.7, 4.6)
7'' β	3.59	1.43
8'' β	1.31	1.46
9'' α	2.13	1.89
11'' α	1.38	1.51
11'' β	1.38	1.51
12'' α		
12'' β	3.76 q (3.6)	3.95 t (2.8)
14'' α	1.95 td (11.4, 7.5)	1.60
15'' α	0.90	1.07 qd (11.8, 5.7)
15'' β	1.61	1.60
16'' α	1.43	1.85
16'' β	1.27	1.27
17'' α	1.76	1.83
18''	0.51 s	0.69 s
19''	0.80 s	0.93 s
20''	1.21	1.43
21''	0.92 d (6.4)	1.02 d (6.4)
22''a	1.67	1.79
22''b	1.18	1.33
23''a	2.16	2.27 ddd (14.1, 9.7, 4.8)
23''b	2.05	2.13 ddd (14.1, 9.5, 7.2)
25''	4.26 td (5.8, 1.0)	4.13 s
27''	6.50 t (1.0)	-
6	8.74 s	8.32 s
1'	6.14 t (6.1)	6.24 dd (7.1, 6.3)
2'a	2.39 ddd (13.5, 6.1, 4.2)	2.31 ddd (13.6, 6.3, 3.6)
2'b	2.02 dt (13.5, 6.1)	2.21 ddd (13.6, 7.1, 6.1)
3'	3.22 m	4.40 ddd (6.1, 3.6, 3.2)
4'	3.91 q (3.8)	3.94 ddd (3.5, 3.2, 3.1)
5'a	3.66 ddd (12.1, 5.2, 3.8)	3.81 dd (12.0, 3.1)
5'b	3.60 ddd (12.1, 5.2, 3.8)	3.73 dd (12.0, 3.5)

^aOther signals: 3.09 (d, 1H, $J = 3.5$, OH-7''); 4.09 (d, 1H, $J = 3.6$, OH-12''); 4.32 (d, 1H, $J = 4.4$, OH-3''); 5.12 (t, 1H, $J = 5.2$, OH-5'); 5.29 (d, 1H, $J = 4.3$, OH-3'); 8.41 (t, 1H, $J = 5.8$, NH).





Table S6. ^{13}C NMR of uracil - bile acids conjugates
 Compound

Carbon	9d	8e
	125.7 MHz DMSO- d_6	125.7 MHz CD $_3$ OD
1"	35.51	36.42
2"	30.60	31.05
3"	70.64	72.53
4"	39.79	37.17
5"	41.72	43.61
6"	35.08	28.40
7"	66.44	27.47
8"	39.63	37.44
9"	26.40	34.79
10"	34.59	35.30
11"	27.54	29.87
12"	71.20	74.05
13"	45.91	47.56
14"	41.57	49.26
15"	22.99	24.92
16"	28.75	28.67
17"	46.32	48.07
18"	12.45	13.25
19"	22.83	23.71
20"	35.25	36.72
21"	17.27	17.69
22"	31.91	33.15
23"	32.55	33.91
24"	173.06	176.43
25"	35.74	30.36
26"	154.83	90.20
27"	101.34	75.03
2	153.96	151.17
4	171.38	164.61
5	106.07	99.99
6	138.06	145.45
1'	87.78	87.03
2'	41.44	41.73
3'	69.92	71.12
4'	88.43	89.18
5'	61.00	62.62

